You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 296 No. 10, September 13, 2006 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Letters
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Contact me when this article is cited
 Related Content
 •Related articles
 •Similar articles in JAMA
 Topic Collections
 •Pacemakers/ Defibrillators
 •Cardiovascular Intervention
 •Alert me on articles by topic

Antiarrhythmic Therapy for Prevention of Implantable Cardioverter Defibrillator Shocks—Reply

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In Reply: Dr Wase raises the issue of inappropriately delivered ICD shocks. In reviewing all ICD shocks in our trial, those not potentially influenced by antiarrhythmic drugs (ie, due to lead fractures or dislodgements) were rare. Only 1 inappropriate shock was delivered for T-wave oversensing and the rest were delivered for supraventricular tachyarrhythmias (primarily atrial fibrillation). None of the patients in the OPTIC study had hypertrophic cardiomyopathy, a condition in which T-wave oversensing by the ICD is more likely to result in inappropriate shock delivery. We did not enroll patients in our study who presented with arrhythmic storms; these patients usually require antiarrhythmic therapy.

Dr Coceani raises the question of the antiarrhythmic potential of the various beta-blockers used in our trial. There is some evidence of specific antiarrhythmic efficacy of carvedilol in experimental studies.1-2 However, no properly designed clinical trial has compared the effects of carvedilol vs those of metoprolol . . . [Full Text of this Article]

Stefan H. Hohnloser, MD
J. W. Goethe University
Frankfurt, Germany

Robin S. Roberts, MTech
McMaster University
Hamilton, Ontario

Eric Fain, MD
St Jude Medical
Sylmar, Calif

Stuart J. Connolly, MD
connostu@phri.ca
McMaster University
Hamilton, Ontario


RELATED ARTICLES

Antiarrhythmic Therapy for Prevention of Implantable Cardioverter Defibrillator Shocks
Abdul Wase
JAMA. 2006;296(10):1229.
EXTRACT | FULL TEXT  

Antiarrhythmic Therapy for Prevention of Implantable Cardioverter Defibrillator Shocks
Michele Coceani
JAMA. 2006;296(10):1229-1230.
EXTRACT | FULL TEXT  

Comparison of {beta}-Blockers, Amiodarone Plus {beta}-Blockers, or Sotalol for Prevention of Shocks From Implantable Cardioverter Defibrillators: The OPTIC Study: A Randomized Trial
Stuart J. Connolly, Paul Dorian, Robin S. Roberts, Michael Gent, Steven Bailin, Eric S. Fain, Kevin Thorpe, Jean Champagne, Mario Talajic, Benoit Coutu, Gerian C. Gronefeld, Stefan H. Hohnloser, and for the Optimal Pharmacological Therapy in Cardioverter Defibrillator Patients (OPTIC) Investigators
JAMA. 2006;295(2):165-171.
ABSTRACT | FULL TEXT  






HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2006 American Medical Association. All Rights Reserved.